Categories
Recommended Sites
- Actos Lawsuit
- Bing Search
- Conscious Evolution
- Free Health Insurance Quote
- Free Loan Quote
- Genistein Net
- Google Search
- HGH
- HGH Injections
- HGH Prescription
- HGH Side Effects
- HGH Therapy
- Hormone Therapy
- Injectable Testosterone
- Medical School Review
- NYC Bed Bugs Pest Control
- SEO Web Design
- Start Your Own Internet Services Company
- Testosterone
- Testosterone Replacement Therapy
- WholeSale Domain Names
Category Archives: Stem Cell Human Trials
Bio-Matrix Subsidiary "First in Class" Approach to Stem Cell Medicine
SAN DIEGO, CA–(Marketwire -05/03/12)- Regen BioPharma (Regen), Inc. a newly-formed subsidiary of Bio-Matrix Scientific Group, Inc. (BMSN.PK – News) (BMSN.PK – News), unveiled today its operational plan for its “Super-Incubator” stem cell company. Continue reading
Posted in Stem Cell Human Trials
Tagged a-packages-for, academia-given, agencies-regen, business, development, intellectual, regulatory, scientific, space, spun-off-either, stem-cell, technologies, technology, therapeutic, through-the-fda
Comments Off
Neuralstem Chief Scientific Officer To Present At Spinal Cord Injury Conference In China
ROCKVILLE, Md., April 25, 2012 /PRNewswire/ –Neuralstem, Inc. (CUR) announced that Karl Johe, PhD, Chairman and Chief Scientific Officer, will present at the Fourth International Spinal Cord Injury Treatments and Trials Symposium, in Xi’an, China on Friday, May 4, at 1:00 PM (http://iscitt.org/iscitt4/). Continue reading
Posted in Stem Cell Human Trials
Tagged ability, china-on-friday, development, differentiation, neuralstem, phase, press, private, proprietary, results, safety, spinal-cord, treatment, well-as-provide
Comments Off
MissionIR News – VistaGen Therapeutics Awarded U.S. Stem Cell Technology Patent Covering Methods Used to Test Drug …
Patent covers all mammalian liver stem cells, including human cellsAtlanta, Georgia (PRWEB) April 26, 2012 MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCBB: VSTA), focused on applying stem cell technology for drug rescue and cell therapy Continue reading
Posted in Stem Cell Human Trials
Tagged april, Cell Therapy, for-drug, generate-new, georgia, human-stem, mammalian-liver, mission, rescue-and, rescue-combines, variants-, vista
Comments Off
BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTimes subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today. Continue reading
Posted in Stem Cell Human Trials
Tagged a-base-products, a-gathered-from, a-high-degree, a-research-tool, a-scalable-and, business, data-, europe, highly-purified, israel-, progenitor, science, sciences, technology, weizmann
Comments Off
BioTime’s Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for …
ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTimes subsidiary ReCyte Therapeutics, Inc. Continue reading
Posted in Stem Cell Human Trials
Tagged a-treatment-and, a-wide-array, california, development, developmental, manufacturing, medical, president, professor, regeneration, south-korea, therapeutics, treatment, united-states
Comments Off
BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07
ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. Continue reading
Posted in Stem Cell Human Trials
Tagged a-blood-plasma, a-high-unmet, a-treatment-and, a-wide-array, arnold-caplan, corporation, developmental, diagnostic, director, manufacturing, south-korea, therapeutics, treatment, western-reserve
Comments Off
BioTime’s Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development
ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving, Ph.D., the CEO of BioTimes subsidiary Cell Cure Neurosciences, Ltd. Continue reading
Posted in Stem Cell Human Trials
Tagged a-blood-plasma, a-high-unmet, business, california, development, developmental, diagnostic, international, manufacturing, product, south-korea, widely-believed
Comments Off
BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells
ALAMEDA, Calif.–(BUSINESS WIRE)– BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoarthritis Continue reading
Posted in Stem Cell Human Trials
Tagged a-large-scale-, a-scale-needed, aging, current, director, product, study, which-the-cells
Comments Off
Former Alabama football players get stem cell injections from Gulf Shores doctor
MOBILE, Alabama — At the end of this past season with the Oakland Raiders, an aching Rolando McClain gave an assignment to his agent: Find out more about stem cell therapies for injuries, like other athletes are trying. Continue reading
Posted in Stem Cell Human Trials
Tagged a-high-ankle, a-lot-better, alabama, cells, linebackers, oakland, oakland-raiders, raiders, same-procedure-
Comments Off
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
ALAMEDA, Calif. Continue reading
Posted in Stem Cell Human Trials
Tagged a-gathered-from, a-license-from, acquisition, cell-lines, databases, launched-at-the, life--, market-the-new, research, science, sciences, shares-as-part, transaction, weizmann
Comments Off